This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Judy E. Garber, MD, MPH; Deborah Schrag, MD

JAMA. 1996;275(24):1928-1929.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Testing for inherited cancer predisposition syndromes is becoming ever more widely available. In this transition period, health care professionals from many disciplines will be forced to integrate the rapidly evolving technologies and expanding knowledge base of cancer genetics into their patient care paradigms. They will also find it necessary to consider unfamiliar and complex issues with patients and their families while facing pressures to reduce time per patient visit and referral.

See also p 1885.

Many thoughtful and qualified lay and professional groups are concerned that the availability of predisposition testing outside the research setting may be premature: critical clinical questions have yet to be answered, clinicians appropriately educated, test characteristics adequately defined, and sufficient social protections put into place.^1-5 The risk of insurance and employment discrimination alone may prevent genetics from realizing its true potential for good.⁶

The availability of commercial testing for common cancer susceptibility genes . . . [Full Text PDF of this Article]

Author Affiliations
From the Dana-Farber Cancer Institute, Boston, Mass.

Footnotes
Reprints: Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute, Division of Cancer Epidemiology and Control, 44 Binney St, Mayer 3A31, Boston, MA 02115.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?